Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22319584 | 0.83 | ADORA2A (0.50) | KMT2AHTTL3MBTL1ADORA2AADORA1 | |
| SCHEMBL21628364 | 0.82 | KMT2A (0.60) | KMT2AHTTL3MBTL1ADORA2AADORA1 | |
| SCHEMBL28729368 | 0.82 | KDM4E (0.55) | KMT2AHTTL3MBTL1ADORA2AADORA1 | |
| SCHEMBL21628363 | 0.80 | KMT2A (0.76) | KMT2AHTTL3MBTL1ADORA2AADORA1 | |
| SCHEMBL21628361 | 0.80 | ADORA2A (0.67) | KMT2AHTTL3MBTL1ADORA2AADORA1 | |
| SCHEMBL28729939 | 0.80 | KMT2A (0.57) | KMT2AHTTL3MBTL1ADORA2AADORA1 | |
| SCHEMBL29483962 | 0.76 | KMT2A (0.46) | KMT2AHTTL3MBTL1ADORA2AADORA1 | |
| SCHEMBL21628359 | 0.76 | KMT2A (0.46) | KMT2AHTTL3MBTL1ADORA2AADORA1 | |
| SCHEMBL20788191 | 0.72 | KMT2A (0.76) | KMT2AHTTL3MBTL1ADORA2AADORA1 | |
| SCHEMBL15760229 | 0.72 | KMT2A (0.76) | KMT2AHTTL3MBTL1ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108570038-B | Dihydroquinoxaline bromodomain recognition protein inhibitor, preparation method and application thereof | 中国科学院上海药物研究所 | 2021-09-28 | — | — | CN | disclosed |
| US-11078188-B2 | Dihydroquinoxaline bromodomain recognition protein inhibitor, preparation method and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2021-08-03 | — | — | US | disclosed |
| US-20200031802-A1 | DIHYDROQUINOXALINE BROMODOMAIN RECOGNITION PROTEIN INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031802-A1 | DIHYDROQUINOXALINE BROMODOMAIN RECOGNITION PROTEIN INHIBITOR, PREPARATION METHOD AND USE THEREOF | BRD4, BRPF3, BRD1 | KMT2A 1541/4885HTT 4013/4885L3MBTL1 3971/4885 |
| US-11078188-B2 | Dihydroquinoxaline bromodomain recognition protein inhibitor, preparation method and use thereof | BRD4, BRPF3, BRD1 | KMT2A 1541/4885HTT 4013/4885L3MBTL1 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.